HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER
Clinical trials for HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radioactive cancer drug trial seeks to target multiple advanced tumors
Disease control Recruiting nowThis early-stage study is testing a new radioactive drug treatment for people with advanced solid tumors that have stopped responding to standard therapies. Researchers will first use a special imaging scan to see if patients' tumors are likely to respond, then give the radioacti…
Matched conditions: HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Novartis tests 'Smart Bomb' radiation therapy against four deadly cancers
Disease control Recruiting nowThis early-stage study is testing a new radioactive drug called [177Lu]Lu-NNS309 in patients with advanced pancreatic, lung, breast, or colorectal cancers that have stopped responding to standard treatments. Researchers will first use a special imaging scan to see if patients' tu…
Matched conditions: HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 04, 2026 15:29 UTC